Teitur Trophics
PrivateLast Round
Series A
Mar 14, 2023
Total Funding Raised
$33.28M
Company Overview
Teitur Trophics operates in Healthcare & Life Sciences and is based in Aarhus. Its latest recorded funding round was a Series A round in March 2023.
Teitur Trophics is a biotechnology company that develops first-in-class peptide-based therapies for neurodegenerative diseases such as Parkinson's and Huntington's Disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Teitur Trophics Comparables
Compare Teitur Trophics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vesper Bio ApS | 84% | |
| Johnson & Johnson | 81% | |
| Axoltis Pharma | 78% |
For institutional investors. Book with your work email.
Teitur Trophics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 14, 2023 | ||||
| Seed | Dec 21, 2021 | ||||
| Seed | Oct 1, 2020 | ||||
| Accelerator | Jan 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Teitur Trophics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovestor | Series A |
| Industrifonden | Series A |
| P53 Invest | Series A |
| Sunstone Life Science Ventures | Series A, Seed |
| BioInnovation Institute | Accelerator, Seed |
| Sound Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
Monthly visitors grew 829% MoM, from 124 to 1.2K.
- Mar 14, 2023
$30M round led by Sound Bioventures and Sunstone Life Science Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 10, 2026
Teitur Trophics develops a panel of mechanism-related biomarkers that assess target engagement through its Phase I trial in Netherlands, and the biomarkers are measurable in cerebrospinal fluid.
For institutional investors. Book with your work email.
Teitur Trophics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Teitur Trophics's valuation, stock price, and market status.
Is Teitur Trophics a public or private company?
Teitur Trophics is a private company.
What is the current stock price of Teitur Trophics?
Teitur Trophics is a private company, so its shares have no public market price. Caplight tracks Teitur Trophics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Teitur Trophics worth (valuation)?
Valuation information for Teitur Trophics is not publicly available.
Can I buy Teitur Trophics stock?
Teitur Trophics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Teitur Trophics's last funding round?
Teitur Trophics's most recent funding round was Series A on March 14, 2023.
Who are the main investors in Teitur Trophics?
Key investors in Teitur Trophics include Sunstone Life Science Ventures, BioInnovation Institute, Sound Bioventures.
Will Teitur Trophics IPO soon?
No public IPO plans have been announced for Teitur Trophics.
How can I track Teitur Trophics secondary market activity?
Caplight tracks bids, offers, and trades in Teitur Trophics's shares on secondary markets.